| Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
---|---|---|---|
(n = 381) | (n = 105) | (n = 486) | |
Female, n (%) | 318 (83.5) | 86 (81.9) | 404 (83.1) |
Age in years, mean (SD) | 53.5 (11.2) | 49.3 (11.7) | 52.6 (11.4) |
Disease duration in years, mean (range) | 7.8 (0.4–38.0) | 6.1 (0.4–45.0) | 7.4 (0.4–45.0) |
Tender joint counta, n | 16.1 | 17.0 | 16.3 |
Swollen joint counta, n | 13.4 | 14.3 | 13.6 |
HAQ-DIb score | 1.23 | 1.22 | 1.23 |
DAS28-4(ESR) score | 6.0 | 6.1 | 6.0 |
DAS28-3(CRP) score | 5.0 | 5.2 | 5.1 |
ESR, mm/h | 50.7 | 47.7 | 50.1 |
CRP, mg/L | 24.1 | 27.4 | 24.9 |
Concomitant methotrexate, n (%) | 196 (51.4) | 26 (24.8) | 222 (45.7) |
Concomitant systemic corticosteroids, n (%) | 256 (67.2) | 80 (76.2) | 336 (69.1) |